Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

Completed · Phase 1

Conditions studied: Advanced Breast Cancer

In brief

The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxane and an anthracycline

Key facts

Study ID

NCT00452673

Run by

Bristol-Myers Squibb

People needed

52

Starts

2007-06-01

Expected to finish

2012-10-01

Last updated by the study team

2015-03-24

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female with advanced breast cancer previously treated with a taxane and an anthracycline
• No pleural or pericardial effusion
• Not receiving anticoagulants

Where it is running

• City Of Hope National Medical Center — Duarte, California, United States
• Northwestern University Feinberg School Of Medicine — Chicago, Illinois, United States
• New York Presbyterian Hospital — New York, New York, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• Local Institution — Rozzano, Milano, Italy
• Local Institution — Barcelona, Spain
• Local Institution — Seville, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.